skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Hypoxic cell turnover in different solid tumor lines

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [4];  [2]
  1. Department of Radiation Oncology, Radboud University Medical Center Nijmegen, Nijmegen (Netherlands) and Department of Radiation Sciences, Umeaa University, Umeaa (Sweden)
  2. Department of Radiation Oncology, Radboud University Medical Center Nijmegen, Nijmegen (Netherlands)
  3. Division of Experimental Therapy, Netherlands Cancer Institute, Amsterdam (Netherlands)
  4. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC (United States)

Purpose: Most solid tumors contain hypoxic cells, and the amount of tumor hypoxia has been shown to have a negative impact on the outcome of radiotherapy. The efficacy of combined modality treatments depends both on the sequence and timing of the treatments. Hypoxic cell turnover in tumors may be important for optimal scheduling of combined modality treatments, especially when hypoxic cell targeting is involved. Methods and Materials: Previously we have shown that a double bioreductive hypoxic marker assay could be used to detect changes of tumor hypoxia in relation to the tumor vasculature after carbogen and hydralazine treatments. This assay was used in the current study to establish the turnover rate of hypoxic cells in three different tumor models. The first hypoxic marker, pimonidazole, was administered at variable times before tumor harvest, and the second hypoxic marker, CCI-103F, was injected at a fixed time before harvest. Hypoxic cell turnover was defined as loss of pimonidazole (first marker) relative to CCI-103F (second marker). Results: The half-life of hypoxic cell turnover was 17 h in the murine C38 colon carcinoma line, 23 h and 49 h in the human xenograft lines MEC82 and SCCNij3, respectively. Within 24 h, loss of pimonidazole-stained areas in C38 and MEC82 occurred concurrent with the appearance of pimonidazole positive cell debris in necrotic regions. In C38 and MEC82, most of the hypoxic cells had disappeared after 48 h, whereas in SCCNij3, viable cells that had been labeled with pimonidazole were still observed after 5 days. Conclusions: The present study demonstrates that the double hypoxia marker assay can be used to study changes in both the proportion of hypoxic tumor cells and their lifespan at the same time. The present study shows that large differences in hypoxic cell turnover rates may exist among tumor lines, with half-lives ranging from 17-49 h.

OSTI ID:
20698627
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 62, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2005.03.049; PII: S0360-3016(05)00584-5; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Evaluation and Immunohistochemical Qualification of Carbogen-Induced ΔR{sub 2}* as a Noninvasive Imaging Biomarker of Improved Tumor Oxygenation
Journal Article · Sun Sep 01 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698627

Irradiation-Dependent Effects on Tumor Perfusion and Endogenous and Exogenous Hypoxia Markers in an A549 Xenograft Model
Journal Article · Sun Aug 01 00:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698627

ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation
Journal Article · Tue Feb 01 00:00:00 EST 1994 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:20698627